Ther-Rx Corporation and Perrigo Co. announced that Gynazole-1 (Butoconazole Nitrate Vaginal Cream USP, 2%), indicated for the local treatment of yeast infections (vulvovaginal candidiasis infections caused by Candida) in non-pregnant women, is now available for prescribing. Gynazole-1 is available at major national and regional retail pharmacy chains across the country.

Ther-Rx has partnered with Perrigo to manufacture Gynazole-1. Perrigo is a manufacturer of prescription drugs in the U.S. market that has been inspected and approved by the U.S. Food and Drug Administration (FDA) as being in compliance with current Good Manufacturing Practice requirements to manufacture Gynazole-1. Gynazole-1 (Butoconazole Nitrate Vaginal Cream USP, 2%) is indicated for the local treatment of vulvovaginal candidiasis (infections caused by Candida). The diagnosis should be confirmed by KOH smears and/or cultures.